AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

MarketsSign up free
🇿🇦

Bevacizumab in South Africa

10 products registered with SAHPRA — 8 active

Brand / ProductReg. No.HolderStatusExpires
BEVACIZUMAB 400 EQUITY56/26/0467Equity Pharmaceutical (Pty) Ltdactive4 Feb 2030
BEVACIZUMAB 100 EQUITY56/26/0466Equity Pharmaceutical (Pty) Ltdactive4 Feb 2030
BEVACIZUMAB 400 CIPLA57/30.1/0233Cipla Medpro (Pty) Ltdactive19 Nov 2029
BEVACIZUMAB 100 CIPLA57/30.1/0232Cipla Medpro (Pty) Ltdactive19 Nov 2029
RIQVIVA 40056/26/0605Dr ReddyÆs Laboratories (Pty) Ltdactive14 Nov 2028
RIQVIVA 10056/26/0604Dr ReddyÆs Laboratories (Pty) Ltdactive14 Nov 2028
MVASI 400 mg/16 ml56/26/0230Amgen South Africa (Pty)Ltdsuspended18 Mar 2025
MVASI 100 mg/4 ml56/26/0229Amgen South Africa (Pty)Ltdsuspended18 Mar 2025
AVASTIN 400A39/26/0315Roche Products (Pty) Ltdactive1 Jan 1900
AVASTIN 100A39/26/0314Roche Products (Pty) Ltdactive1 Jan 1900

Bevacizumab — SAHPRA Registration Details

SAHPRA (South Africa) has 10 registered products containing Bevacizumab, of which 8 are currently active. Data is sourced directly from the official SAHPRA drug register and refreshed daily.

Track Bevacizumab registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.